JBM HEALTHCARE (SEHK: 2161) has announced its financial results for the year ended March 31, 2026. The company reported revenue of approximately HK$835 million, representing an increase of about 6.7% year-on-year.

Profit attributable to equity holders of the company was around HK$201 million, marking a rise of approximately 1.9% compared to the previous year. Earnings per share stood at 24.63 HK cents, with a final dividend of 7.35 HK cents per share declared.

The company attributed the revenue growth primarily to the robust performance of its Branded Medicines and Branded Chinese Medicine segments, which was partially offset by a weaker performance in the Health Supplements division. Supported by solid market demand and effective marketing initiatives, the Branded Medicines segment saw a revenue increase of HK$7.8 million, reflecting stable sales momentum and enhanced promotional efforts. Meanwhile, the Branded Chinese Medicine segment recorded a revenue growth of HK$62.9 million.

These gains were partly offset by a revenue decline of HK$18.4 million in the Health Supplements segment, primarily due to a refined and simplified product mix and softer consumer demand. The three segments contributed 34%, 56%, and 10% respectively to the total revenue.